- Conditions
- Bladder Cancer
- Interventions
- filgrastim, cisplatin, doxorubicin hydrochloride, methotrexate, vinblastine sulfate, conventional surgery
- Biological · Drug · Procedure
- Lead sponsor
- Memorial Sloan Kettering Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1996 – 2003
- U.S. locations
- 1
- States / cities
- New York, New York
Search Results
Search by objective public record fields.
Search by query text, NCT ID, condition, intervention, sponsor, city, state, recruitment status, phase, study type, healthy volunteer eligibility, sex, or age. Results are retrieved from ClinicalTrials.gov and synchronized into the directory. Search pages remain noindex by default.
Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.
Showing 1–24
of 117
matching trials from the live ClinicalTrials.gov search.
Local D1 index available.
- Conditions
- Melanoma
- Interventions
- Palonosetron
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years to 65 Years
- Enrollment
- 30 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2006 – 2009
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- carboplatin, cisplatin, docetaxel, etoposide, paclitaxel, vinblastine sulfate, vinorelbine tartrate, gene expression analysis, positron emission tomography, fludeoxyglucose F 18, radiation therapy
- Drug · Genetic · Procedure + 1 more
- Lead sponsor
- American College of Radiology Imaging Network
- Network
- Eligibility
- 18 Years and older
- Enrollment
- 250 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2005
- U.S. locations
- 46
- States / cities
- Birmingham, Alabama • Scottsdale, Arizona • Los Angeles, California + 38 more
- Conditions
- Ann Arbor Stage III Hodgkin Lymphoma, Ann Arbor Stage III Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage III Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage III Nodular Sclerosis Classic Hodgkin Lymphoma, Ann Arbor Stage IV Hodgkin Lymphoma, Ann Arbor Stage IV Lymphocyte-Depleted Classic Hodgkin Lymphoma, Ann Arbor Stage IV Mixed Cellularity Classic Hodgkin Lymphoma, Ann Arbor Stage IV Nodular Sclerosis Classic Hodgkin Lymphoma, Classic Hodgkin Lymphoma, Lymphocyte-Rich Classic Hodgkin Lymphoma
- Interventions
- Biospecimen Collection, Brentuximab Vedotin, Computed Tomography, Dacarbazine, Doxorubicin Hydrochloride, Filgrastim, Magnetic Resonance Imaging, Nivolumab, Pegfilgrastim, Positron Emission Tomography, Quality-of-Life Assessment, Questionnaire Administration, Radiation Therapy, Vinblastine Sulfate
- Procedure · Drug · Biological + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 994 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2027
- U.S. locations
- 711
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 472 more
- Conditions
- Leukemia
- Interventions
- Prednisone, Vinblastin, 6-mercaptopuroine, Leucovorin, Methotrexate, Vinblastine, Prednisone
- Drug
- Lead sponsor
- University of New Mexico
- Other
- Eligibility
- Up to 18 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023
- U.S. locations
- 1
- States / cities
- Albuquerque, New Mexico
- Conditions
- Stage II Bladder Cancer AJCC v8, Stage IIIA Bladder Cancer AJCC v8, Muscle Invasive Bladder Carcinoma
- Interventions
- Cisplatin, Doxorubicin, Methotrexate, Pegfilgrastim, Pembrolizumab, Radical Cystectomy, Vinblastine Sulfate
- Drug · Biological · Procedure
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 17 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2020 – 2025
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Hodgkin Lymphoma
- Interventions
- Nivolumab, Doxorubicin Hydrochloride, Vinblastine, Dacarbazine
- Drug
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 2 Years to 21 Years
- Enrollment
- 15 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2026 – 2032
- U.S. locations
- 1
- States / cities
- Houston, Texas
- Conditions
- Classical Hodgkin Lymphoma
- Interventions
- Dacarbazine, Doxorubicin Hydrochloride, Laboratory Biomarker Analysis, Pembrolizumab, Vinblastine
- Drug · Other · Biological
- Lead sponsor
- University of Washington
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2019 – 2023
- U.S. locations
- 1
- States / cities
- Seattle, Washington
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, Stanford V regimen, doxorubicin hydrochloride, etoposide, mechlorethamine hydrochloride, prednisone, vinblastine sulfate, vincristine sulfate, radiation therapy
- Biological · Drug · Radiation
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 16 Years to 60 Years
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1995 – 2001
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Prostate Cancer
- Interventions
- Docetaxel, Doxorubicin hydrochloride, Estramustine phosphate sodium, Ketoconazole, Prednisone, Vinblastine, Strontium chloride Sr 89, Dexamethasone
- Drug · Radiation
- Lead sponsor
- M.D. Anderson Cancer Center
- Other
- Eligibility
- 18 Years and older · Male only
- Enrollment
- 265 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 2002
- U.S. locations
- 40
- States / cities
- Gainesville, Georgia • Savannah, Georgia • Hines, Illinois + 23 more
- Conditions
- Recurrent Low Grade Astrocytoma, Recurrent WHO Grade 2 Glioma, Refractory Low Grade Astrocytoma, Refractory Low Grade Glioma, Refractory WHO Grade 1 Glioma
- Interventions
- Biospecimen Collection, Magnetic Resonance Imaging, Quality-of-Life Assessment, Questionnaire Administration, Selumetinib Sulfate, Vinblastine Sulfate
- Procedure · Other · Drug
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 2 Years to 25 Years
- Enrollment
- 300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2021 – 2026
- U.S. locations
- 91
- States / cities
- Birmingham, Alabama • Little Rock, Arkansas • Loma Linda, California + 77 more
- Conditions
- Hodgkin Lymphoma
- Interventions
- brentuximab vedotin, doxorubicin, bleomycin, vinblastine, dacarbazine
- Drug
- Lead sponsor
- Takeda
- Industry
- Eligibility
- 18 Years and older
- Enrollment
- 1,334 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2012 – 2026
- U.S. locations
- 83
- States / cities
- Birmingham, Alabama • Gilbert, Arizona • Tucson, Arizona + 80 more
- Conditions
- HIV Infections, Hodgkin's Disease
- Interventions
- Vinblastine sulfate, Dacarbazine, Filgrastim, Bleomycin sulfate, Doxorubicin hydrochloride
- Drug
- Lead sponsor
- National Institute of Allergy and Infectious Diseases (NIAID)
- NIH
- Eligibility
- 12 Years and older
- Enrollment
- 27 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Ends 1999
- U.S. locations
- 8
- States / cities
- Birmingham, Alabama • Los Angeles, California • Chicago, Illinois + 4 more
- Conditions
- Lymphoma
- Interventions
- bleomycin sulfate, carmustine, cyclophosphamide, dacarbazine, doxorubicin hydrochloride, etoposide, vinblastine, peripheral blood stem cell transplantation
- Biological · Drug · Procedure
- Lead sponsor
- SWOG Cancer Research Network
- Network
- Eligibility
- 15 Years to 65 Years
- Enrollment
- 11 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2000 – 2005
- U.S. locations
- 47
- States / cities
- Birmingham, Alabama • La Jolla, California • San Francisco, California + 29 more
- Conditions
- Lugano Classification Limited Stage Hodgkin Lymphoma AJCC v8
- Interventions
- Biospecimen Collection, Bleomycin Sulfate, Brentuximab Vedotin, Computed Tomography, Cyclophosphamide, Dacarbazine, Doxorubicin Hydrochloride, Etoposide, Etoposide Phosphate, Fludeoxyglucose F-18, Involved-site Radiation Therapy, Magnetic Resonance Imaging, Nivolumab, Positron Emission Tomography, Prednisolone, Prednisone, Procarbazine Hydrochloride, Questionnaire Administration, Vinblastine Sulfate, Vincristine Sulfate
- Procedure · Biological · Drug + 2 more
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 5 Years to 60 Years
- Enrollment
- 1,875 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2023 – 2031
- U.S. locations
- 400
- States / cities
- Birmingham, Alabama • Mobile, Alabama • Anchorage, Alaska + 296 more
- Conditions
- Stage IV Melanoma
- Interventions
- recombinant interferon alfa-2b, cisplatin, sodium stibogluconate, dacarbazine, vinblastine
- Biological · Drug
- Lead sponsor
- Case Comprehensive Cancer Center
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 22 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2007 – 2012
- U.S. locations
- 1
- States / cities
- Cleveland, Ohio
- Conditions
- Lymphoma
- Interventions
- Doxorubicin, Bleomycin, Vinblastine, Dacarbazine, Vincristine, Mechlorethamine, Etoposide, Prednisone, Cyclophosphamide, Radiotherapy
- Drug · Radiation
- Lead sponsor
- Eastern Cooperative Oncology Group
- Network
- Eligibility
- 16 Years and older
- Enrollment
- 854 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1999 – 2016
- U.S. locations
- 517
- States / cities
- Mobile, Alabama • Phoenix, Arizona • Tucson, Arizona + 329 more
- Conditions
- Lymphoma
- Interventions
- Bleomycin sulfate, Stanford V regimen, Doxorubicin hydrochloride, Etoposide, Mechlorethamine hydrochloride, Prednisone, Vinblastine, Vincristine sulfate
- Biological · Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 50 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 1989 – 2015
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Disease, Hodgkin
- Interventions
- brentuximab vedotin, doxorubicin, vinblastine, dacarbazine, bleomycin
- Drug
- Lead sponsor
- Seagen Inc.
- Industry
- Eligibility
- 18 Years to 60 Years
- Enrollment
- 51 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2012
- U.S. locations
- 3
- States / cities
- Rochester, Minnesota • Chapel Hill, North Carolina • Houston, Texas
- Conditions
- Lung Cancer
- Interventions
- cisplatin, etoposide, vinblastine sulfate, vindesine, vinorelbine tartrate, radiation therapy
- Drug · Radiation
- Lead sponsor
- Gustave Roussy, Cancer Campus, Grand Paris
- Other
- Eligibility
- 18 Years to 75 Years
- Enrollment
- 3,300 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- Started 1995
- U.S. locations
- 2
- States / cities
- Atlantis, Florida • Boston, Massachusetts
- Conditions
- Hodgkin Lymphoma
- Interventions
- bendamustine, Etoposide, Doxorubicin, Bleomycin, Vincristine, Vinblastine, Prednisone, Filgrastim, Brentuximab Vedotin, Cyclophosphamide, DTIC, Quality of Life Measurements, Radiotherapy
- Drug · Other · Radiation
- Lead sponsor
- St. Jude Children's Research Hospital
- Other
- Eligibility
- Up to 25 Years
- Enrollment
- 232 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2018 – 2028
- U.S. locations
- 8
- States / cities
- Palo Alto, California • Peoria, Illinois • Baton Rouge, Louisiana + 4 more
- Conditions
- Hodgkin's Lymphoma
- Interventions
- ABVD chemotherapy
- Drug
- Lead sponsor
- Weill Medical College of Cornell University
- Other
- Eligibility
- 18 Years and older
- Enrollment
- 6 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2008 – 2011
- U.S. locations
- 1
- States / cities
- New York, New York
- Conditions
- Hodgkin Disease
- Interventions
- Doxorubicin, Vinblastine, Cyclophosphamide, Etoposide, Vincristine, Bleomycin, Gemcitabine, Vinorelbine, Prednisone
- Drug
- Lead sponsor
- Stanford University
- Other
- Eligibility
- 18 Years to 70 Years
- Enrollment
- 45 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2001 – 2006
- U.S. locations
- 1
- States / cities
- Stanford, California
- Conditions
- Recurrent Melanoma, Stage IV Skin Melanoma
- Interventions
- Cisplatin, Gamma-Secretase Inhibitor RO4929097, Laboratory Biomarker Analysis, Pharmacological Study, Temozolomide, Vinblastine Sulfate
- Drug · Other
- Lead sponsor
- National Cancer Institute (NCI)
- NIH
- Eligibility
- 18 Years and older
- Enrollment
- 14 participants
- Healthy volunteers
- Healthy volunteers not accepted
- Timeline
- 2010 – 2015
- U.S. locations
- 1
- States / cities
- New York, New York